Medtronic's heart device monitor:
This article was originally published in Clinica
Executive Summary
Medtronic has obtained approval to CE mark the automatic version of its internet-based monitoring system, CareLink, in the EU. The Minnesota, Minneapolis-based company immediately launched the product onto the European market. The CareLink Network employs Conexus wireless telemetry to automatically transmit data on patients with implanted heart devices, and on the devices themselves, directly to physicians. It can be used to assess the performance of devices such as cardiac resynchronisation therapy-defibrillators (CRT-D) for patients with heart failure and implantable cardioverter defibrillators (ICDs) for patients with arrhythmia. The network can also monitor fluid build-up in the thoracic cavity (a precursor to heart failure) via a proprietary feature called OptiVol Fluid Status Monitoring. Medtronic claims that a non-wireless version of the system is used by 150,000 patients with heart failure or arrhythmia worldwide.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.